Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Radium ra 223 dichloride
Drug ID BADD_D02406
Description Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first approved by the FDA in May 2013 and is currently marketed under the brand name Xofigo, which was formerly called Alpharadin. Xofigo is indicated in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant. The FDA label includes a warning that Radium Ra 223 Dichloride should not be used in women who are pregnant or may become pregnant due to the high risk of fetal harm.
Indications and Usage Not Available
Marketing Status Not Available
ATC Code V10XX03
DrugBank ID DB08913
KEGG ID D10398
MeSH ID C581106
PubChem ID Not Available
TTD Drug ID Not Available
NDC Product Code 50419-208
Synonyms radium Ra 223 dichloride | radium chloride Ra 223 | Xofigo
Chemical Information
Molecular Formula Not Available
CAS Registry Number 444811-40-9
SMILES Not Available
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypertension24.08.02.001--
Hypoaesthesia17.02.06.023-Not Available
Hypogammaglobulinaemia10.03.01.001-Not Available
Hypokalaemia14.05.03.002--
Hyponatraemia14.05.04.002--
Hypotension24.06.03.002--
Hypotonia17.05.02.002; 15.05.04.008-Not Available
Ileus07.13.01.001-
Infection11.01.08.002-Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
Interstitial lung disease22.01.02.003; 10.02.01.033--Not Available
Intestinal obstruction07.13.01.002-Not Available
Iritis10.02.01.022; 06.04.03.002-Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Laboratory test abnormal13.18.01.001-Not Available
Leukopenia01.02.02.001-Not Available
Liver disorder09.01.08.001--Not Available
Loss of consciousness17.02.04.004--Not Available
Lower respiratory tract infection11.01.09.002; 22.07.01.002-Not Available
Lymphadenopathy01.09.01.002-Not Available
Lymphocyte count decreased13.01.06.006-
Lymphoedema01.09.01.006; 24.09.01.001-
Malaise08.01.01.003-
Melaena24.07.02.013; 07.12.02.004-Not Available
Metastases to liver16.22.02.001; 09.04.02.004-Not Available
Metastases to lung16.22.02.002; 22.08.01.005-Not Available
Metastases to spine16.22.02.007; 15.09.03.007-Not Available
Monoplegia17.01.04.003-Not Available
Multiple fractures15.08.02.005; 12.04.02.009-Not Available
Muscular weakness17.05.03.005; 15.05.06.001--
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 10 Pages